CoChat

Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome

Eisenberg, Mark J., Windle, Sarah B., Roy, Nathalie, Old, Wayne, Grondin, François R., Bata, Iqbal, Iskander, Ayman, Lauzon, Claude, Srivastava, Nalin, Clarke, Adam, Cassavar, Daniel, Dion, Danielle, Haught, Herbert, Mehta, Shamir R., Baril, Jean-François, Lambert, Charles, Madan, Mina, Abramson, Beth L., Dehghani, Payam · 2016 · Circulation
Cited by 137

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background—: Less than one-third of smokers hospitalized with an acute coronary syndrome (ACS) remain abstinent following discharge. We assessed whether varenicline, begun in-hospital, is efficacious for smoking cessation following ACS. Methods and Results—: We conducted a multi-center, double-blind, randomized, placebo-controlled trial in which smokers hospitalized with an ACS were randomized to varenicline or placebo for 12 weeks. All patients received low-intensity counseling. The primary end point was point-prevalence smoking abstinence assessed at 24 weeks by 7-day recall and biochemical validation using expired carbon monoxide. A total of 302 patients were randomized (mean age 55±9 years; 75% male; 56% ST-segment elevation myocardial infarction; 38% non-ST-segment elevation myocardial infarction; 6% unstable angina). Patients smoked a mean of 21±11 cigarettes/d at the time of hospitalization and had been smoking for a mean of 36±12 years. At 24 weeks, patients randomized to varenicline had significantly higher rates of smoking abstinence and reduction than patients randomized to placebo. Point-prevalence abstinence rates were 47.3% in the varenicline group and 32.5% in the placebo group ( P =0.012; number needed to treat=6.8). Continuous abstinence rates were 35.8% and 25.8%, respectively ( P =0.081; number needed to treat=10.0), and rates of reduction ≥50% in daily cigarette consumption were 67.4% and 55.6%, respectively ( P =0.05; number needed to treat=8.5). Adverse event rates within 30 days of study drug discontinuation were similar between groups (serious adverse events: varenicline 11.9%, placebo 11.3%; major adverse cardiovascular events: varenicline 4.0%, placebo 4.6%). Conclusions—: Varenicline, initiated in-hospital following ACS, is efficacious for smoking cessation. Future studies are needed to establish safety in these patients. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00794573.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.115.019634

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 137

Metadata

Authors
Eisenberg, M. J., Windle, S. B., Roy, N., Old, W., Grondin, F. R., Bata, I., Iskander, A., Lauzon, C., Srivastava, N., Clarke, A., Cassavar, D., Dion, D., Haught, H., Mehta, S. R., Baril, J.-F., Lambert, C., Madan, M., Abramson, B. L., & Dehghani, P.
Venue
Circulation
Published
2016-01-05
Volume
133
Issue
1
Pages
21-30
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2151343477
Cited by
137
References
5
FWCI
10.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.